TrkB
TrkB (tropomyosin receptor kinase B), encoded by NTRK2, is a neurotrophic tyrosine kinase receptor that mediates the cellular actions of brain-derived neurotrophic factor (BDNF) and contributes to neuronal differentiation, neuroplasticity, and homeostasis[1][2]. Mechanistically, ligand-induced activation of full-length TrkB (TrkB.FL) triggers receptor autophosphorylation and engages intracellular signaling pathways including PI3K, MAPK/ERK, and PLCγ, thereby supporting neurotrophic responses and synaptic function[3][4]. Alternative splicing of NTRK2 generates distinct receptor isoforms, including TrkB.FL and truncated variants such as TrkB.T1, TrkB.T2, and TrkB-T-ShC, which lack the tyrosine kinase domain and therefore differ fundamentally in signaling capacity[2][5]. Compared with TrkB.FL, TrkB.T1 is the major truncated isoform in the adult brain and can negatively regulate full-length receptor signaling through dominant-inhibitory mechanisms while also exhibiting independent biological activities[5][4]. Altered TrkB isoform balance has been associated with neurodegeneration, ischemic injury, amyotrophic lateral sclerosis, spinal muscular atrophy, psychiatric disorders, and cognitive dysfunction, highlighting the importance of isoform-specific regulation in disease biology[2][6][4][7]. In experimental systems, modulation of BDNF-TrkB signaling and manipulation of TrkB isoform expression are widely used to investigate neuronal survival, differentiation, synaptic plasticity, and disease mechanisms, making TrkB a valuable target for mechanistic and translational neuroscience research[3][5][4].
References:
- [1]. Duarte-Ruiz M, et al. Regulation of NTRK2 alternative splicing by PRPF40B controls neural differentiation and synaptic plasticity. Cell Death Dis. 2025 Dec 8;17(1):73. [Content Brief]
- [2]. Li Y, et al. Tropomyosin receptor kinase B (TrkB) signalling: targeted therapy in neurogenic tumours. J Pathol Clin Res. 2023 Mar;9(2):89-99. [Content Brief]
- [3]. TrkB gene information from NCBI.
- [4]. Rabezanahary H, et al. Live virus neutralizing antibodies against pre and post Omicron strains in food and retail workers in Québec, Canada. Heliyon. 2024 May 21;10(10):e31026. [Content Brief]
- [5]. Tessarollo L, et al. TrkB Truncated Isoform Receptors as Transducers and Determinants of BDNF Functions. Front Neurosci. 2022 Mar 7;16:847572. [Content Brief]
- [6]. Vidaurre OG, et al. Imbalance of neurotrophin receptor isoforms TrkB-FL/TrkB-T1 induces neuronal death in excitotoxicity. Cell Death Dis. 2012 Jan 19;3(1):e256. [Content Brief]
- [7]. Chang C, et al. Recent advances in deciphering hippocampus complexity using single-cell transcriptomics. Neurobiol Dis. 2023 Apr;179:106062. [Content Brief]
-
TrkB Related Products (50)
Related Products (50)
-
Antibodies (2)
-
Cannflavin B
0 ImagesSynonyms: CanniflavoneCannflavin B is a flavonoid compound that can be isolated from Cannabis sativa L. Cannflavin B is inhibitors of PGE2 release (IC50: 0.7 μM), mPGES-1 (IC50: 3.7 μM), and 5-lipoxygenase. Cannflavin B has multiple activities such as anti-inflammatory, antioxidant, anti-glycation, anti-ferroptosis, anti-tumor, and anti-Leishmania (IC50: 14 μM). Cannflavin B can also inhibit the TrkB-BDNF signaling pathway.
-
Zurletrectinib
0 ImagesSynonyms: ICP-723Zurletrectinib is a brain-penetrant, orally active TRK inhibitor (TRKA IC50 = 0.81 nM; TRKB IC50 = 0.145 nM; TRKC IC50 = 0.184 nM). Zurletrectinib exhibits stronger activity as a consequence of its augmented binding affinity for TRK kinases. Zurletrectinib exhibits higher activity against most TRK inhibitor resistance mutations (13 out of 18 mutations). Zurletrectinib can be used for the study of glioma.
-
Levomilnacipran hydrochloride
0 ImagesSynonyms: (1S,2R)-Milnacipran hydrochloride; F-2695 hydrochlorideLevomilnacipran ((1S,2R)-Milnacipran) hydrochloride is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran hydrochloride is a serotonin and norepinephrine reuptake inhibitor, with IC50 values of 10.5 nM and 19.0 nM, and Ki values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran hydrochloride has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression.
-
CG428
0 ImagesCG428 is a potent and selective CRBN-dependent tropomyosin receptor kinase (TRK) PROTAC degrader that has anti-tumor activity. CG428 reduces levels of the tropomyosin 3 TPM3-TRKA fusion protein in KM12 colorectal carcinoma cells (DC50 = 0.36 nM) and inhibits downstream PLCγ1 phosphorylation (IC50 = 0.33 nM). CG428 has a higher binding affinity for TRKA than TRKB and TRKC (Kd = 1 nM, 28 nM and 4.2 nM, respectively). CG428 can be used for the research of colorectal carcinoma.
-
TrkA-IN-1
0 ImagesCat. No.: HY-129634CAS No.: 1680179-43-4TrkA-IN-1 is a potent and selective Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 of 99 nM in a cell-based assay. TrkA-IN-1 has analgesic activity.
-
ZEB85
0 ImagesCat. No.: HY-P991413ZEB85 is a human monoclonal antibody (mAb) targeting TrkB. ZEB85 activates TrkB and its downstream cascades, including the ERK, PLCγ, AKT, MAPK signaling pathways and cFOS expression, and enhances neuronal activity. ZEB85 prevents β-amyloid toxicity in cultured hippocampal neurons. ZEB85 is applicable to the research of Alzheimer's disease (AD).
-
CG428-NEG
0 ImagesCat. No.: HY-157542CAS No.: 2714560-39-9CG428-NEG is the negative control of PROTAC CG428 (HY-137465). CG428-NEG binds to TRKA, TRKB and TRKC with high affinity, with Kd values of 0.88 nM, 4.8 nM and 59.8 nM, respectively. CG428-NEG inhibits the growth of cancer cells and reduces the level of TPM3-TRKA fusion protein in cancer cells. CG428-NEG can be used in the research of colorectal cancer.
-
FLY26
0 ImagesCat. No.: HY-172876Purity: 99.66%FLY26 is a selective partial GluN2B antagonist with an IC50 value of 0.64 μM. FLY26 partially inhibits the GluN2B subunit of NMDA receptors, reduces calcium ion influx and reactive oxygen species (ROS) production and activates the BDNF/TrkB/CREB neuroprotective signaling pathway to alleviate neuronal excitotoxicity and mitochondrial dysfunction. FLY26 is promising for research of neurological deficits caused by cerebral ischemia-reperfusion injury.
-
Sitravatinib malate
0 ImagesCat. No.: HY-16961ACAS No.: 2244864-88-6Synonyms: MGCD516 malate; MG-516 malateSitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively. Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment.
-
Fudotinib
0 ImagesCat. No.: HY-176942CAS No.: 2644645-39-4Synonyms: JYP0322Fudotinib (JYP0322) (ROS1-IN-3) is a potent orally active, selective, and CNS-penetrant ROS1 inhibitor. Fudotinib selectively inhibits human wild-type ROS1 and human ROS1G2032R with IC50s of 0.37 and 0.3 nM, respectively, showing 6-130-fold selectivity over TRKA, TRKB, and TRKC. Fudotinib inhibits proliferation of ROS1 fusion-expressing cells, and inhibits tumor growth in mouse xenograft models. Fudotinib can be used for the research of non-small cell lung cancer (NSCLC).
-
DZX19
0 ImagesCat. No.: HY-181871DZX19 (Compound C02) is an orally active, selective TRK inhibitor with a TRKA IC50 value of 1.32 nM, a TRKB IC50 of 2.28 nM, and a TRKC IC50 of 4.05 nM. DZX19 inhibits the kinase activities of wild-type TRKA, TRKA mutants (G595R, F589L, G667C), wild-type TRKB, and wild-type TRKC, and suppresses the phosphorylation of TRKA as well as its downstream AKT and ERK signaling pathways. DZX19 induces apoptosis. DZX19 inhibits tumor growth in a colorectal cancer xenograft mouse model. DZX19 is applicable for the research of colorectal cancer.
-
Trk-IN-7
0 ImagesCat. No.: HY-143557CAS No.: 2383011-61-6
-
TrkB activator-1
0 ImagesCat. No.: HY-175483SCAS No.: 3087336-56-6TrkB activator-1 is a specific, orally active and brain-penetrant tropomyosin receptor kinase B (TrkB) activator. TrkB activator-1 shows potent antidepressant effects through activation of the activates the BDNF (brainderived neurotrophic factor)-Tropomyosin-related kinase B (TrkB)-CREB (cAMP response element binding protein) signaling aixs. TrkB activator-1 increaes neuroplasticity. TrkB activator-1 can be used for the research of neurological disease, such as depression.
-
PTX-BD10-2
0 ImagesCat. No.: HY-148750CAS No.: 1627834-10-9Synonyms: BD10-2PTX-BD10-2 (BD10-2) is an orally active TrkB/C modulator. PTX-BD10-2 ameliorates BFCN degeneration. PTX-BD10-2 restores cholinergic neurite integrity, alleviates cholinergic neurite atrophy. PTX-BD10-2 can be used in the research of Alzheimer's disease.
-
Trk-IN-20
0 ImagesCat. No.: HY-150561CAS No.: 2460924-63-2
-
Licorisoflavan A
0 ImagesCat. No.: HY-N3385CAS No.: 129314-37-0Synonyms: 7-O-Methyllicorisoflavan BLicorisoflavan A (7-O-Methyllicorisoflavan B) is a isoflavan-quinone, that can be isolated from Glycyrrhiza uralensis. Licorisoflavan A exhibits anti-inflammatory and antimicrobial properties. It can inhibit the secretion of IL-6 and chemokines by LPS-stimulated macrophages in a concentration-dependent manner, and also suppress the secretion of MMP-7, MMP-8, and MMP-9 in macrophages. Licorisoflavan A exertes potent antidepressant-like effects involving BDNF-TrkB pathway and AMPA receptors.
